This Low PE, High ROCE Pharma Company Launches Calcium Gluconate Injection in the US; Check Details

On Friday, Indian equity benchmark indices traded higher, with the benchmark Nifty 50 index rising 0.04 per cent to 24,241.35. Amid the market movement, Glenmark Pharmaceuticals share price fell 0.79 per cent to Rs 2,314.40 after Glenmark Pharmaceuticals Inc., USA announced the launch of Calcium Gluconate Injection USP in multiple strengths and a pharmacy bulk package in the US market.

Glenmark Launches Calcium Gluconate Injection in US

Glenmark Pharmaceuticals Inc., USA has announced the launch of Calcium Gluconate Injection USP in the United States. The product is available in 1,000 mg/10 mL (100 mg/mL) single-dose vials, 5,000 mg/50 mL (100 mg/mL) single-dose vials and a 10,000 mg/100 mL (100 mg/mL) pharmacy bulk package.

According to the company, Glenmark's Calcium Gluconate Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Calcium Gluconate Injection, manufactured by Fresenius Kabi USA, LLC. The reference listed drug is associated with NDA 208418.

US Market Recorded USD 69.9 Million Annual Sales

According to IQVIA sales data for the 12-month period ended June 2026, the Calcium Gluconate Injection market covering the 1,000 mg/10 mL, 5,000 mg/50 mL and 10,000 mg/100 mL strengths achieved annual sales of approximately USD 69.9 million. The company stated that the market data includes the brand and all available therapeutic equivalents.

Glenmark has clarified that its product is approved only for the indications listed in its approved label and will be marketed only for those approved indications, which may differ from the approved indications of the reference listed drug.
Also Read - Stock Below Rs 200: This Multibagger Power Transmission Company Wins Lakadia Part A Transmission Project; Share Price Jumps 5%

Focus on US Injectables Business

Commenting on the launch, Marc Kikuchi, President and Business Head, North America, said the launch represents another step towards strengthening Glenmark's US injectables business and expanding its hospital portfolio.

The company stated that the launch is part of its strategy to build a differentiated and sustainable injectables business focused on institutional needs, supply resilience and expanding its presence across the US healthcare system.

Glenmark Pharmaceuticals Business

Glenmark Pharmaceuticals Limited is a global, research-led pharmaceutical company with a focus on innovation and accessibility. The company has 11 manufacturing facilities across four continents, supported by six research and development centres, and has a commercial presence in more than 80 countries.

The company's portfolio includes branded, innovative, generic and consumer health products, with focus areas including respiratory, dermatology and oncology. Glenmark is positioned among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024, according to Scrip 100.

Share your thoughts on this development in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.